Sarepta Therapeutics Inc (SRPT)

12:30 PM

Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness - Yahoo Finance

12:30 PM

12:08 PM

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace

12:08 PM

May 25, 2026

Sarepta Therapeutics Inc (MEX:SRPT) Stock Price, Trades & News - GuruFocus

May 25, 2026

May 24, 2026

Sarepta's Q1 earnings & sales beat estimates, '26 outlook maintained - MSN

May 24, 2026

May 22, 2026

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys - MSN

May 22, 2026

May 22, 2026

Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - TradingView

May 22, 2026

May 22, 2026

1SRPT.MI Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (BIT:1SRPT) - ChartMill

May 22, 2026

May 21, 2026

Understanding the Setup: (SRPT) and Scalable Risk - Stock Traders Daily

May 21, 2026

May 21, 2026

United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com

May 21, 2026

May 20, 2026

My Top 3 Biotech Stocks for May 2026 - The Motley Fool

May 20, 2026

May 20, 2026

Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock - Insider Monkey

May 20, 2026

May 19, 2026

Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - FinancialContent

May 19, 2026

May 19, 2026

10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey

May 19, 2026

May 19, 2026

J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $19 - Moomoo

May 19, 2026

May 19, 2026

Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII

May 19, 2026

May 18, 2026

Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII

May 18, 2026

May 18, 2026

Rare Disease Therapeutics Market 2025-2033 | Market Growth - openPR.com

May 18, 2026

May 18, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 24.58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

May 18, 2026

May 18, 2026

Neuromuscular Disease Therapeutics Market to Reach USD 45.62 - openPR.com

May 18, 2026

May 17, 2026

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News

May 17, 2026

May 17, 2026

Sarepta Therapeutics (SRPT) Q1 earnings and revenues top estimates - MSN

May 17, 2026

May 17, 2026

Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN

May 17, 2026

May 15, 2026

Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $19 - Moomoo

May 15, 2026

May 15, 2026

Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35 - Moomoo

May 15, 2026

May 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 15, 2026

May 14, 2026

Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? - Eastern Progress

May 14, 2026

May 14, 2026

SRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growth - MSN

May 14, 2026

May 14, 2026

Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission - statnews.com

May 14, 2026

May 14, 2026

We Don't Think Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Should Make Shareholders Too Comfortable - Moomoo

May 14, 2026

May 14, 2026

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft Foundations - Yahoo Finance

May 14, 2026

May 14, 2026

Sarepta Therapeutics stock (US8036071004): Q1 earnings beat estimates amid share price decline - AD HOC NEWS

May 14, 2026

May 14, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News - simplywall.st

May 14, 2026

May 13, 2026

SRPT Stock Price Prediction 2025-2026 | Sarepta Therapeutics Inc Forecast - 24/7 Wall St.

May 13, 2026

May 13, 2026

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Business Wire

May 13, 2026

May 13, 2026

Sarepta Therapeutics (NASDAQ: SRPT) files Form 13F showing 1 entry - Stock Titan

May 13, 2026

May 12, 2026

Splicing Patent Eligibility: The Federal Circuit Restores § 101 Eligibility for Engineered Cells in 'REGENXBIO v. Sarepta' - Law.com

May 12, 2026

May 11, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Evaluating the 10.25% Potential Upside in a Challenging Market - DirectorsTalk Interviews

May 11, 2026

May 10, 2026

The Technical Signals Behind (SRPT) That Institutions Follow - Stock Traders Daily

May 10, 2026

May 10, 2026

Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones - Sahm

May 10, 2026

May 09, 2026

A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress - Yahoo Finance

May 09, 2026

May 09, 2026

H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo

May 09, 2026

May 08, 2026

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says - Moomoo

May 08, 2026